Artenimol
Eurartesim (artenimol) is a small molecule pharmaceutical. Artenimol was first approved as Eurartesim on 2011-10-27. It has been approved in Europe to treat malaria.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | — | 8 | 33 | 19 | 7 | 64 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 5 | 6 | 12 | 5 | 8 | 33 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | 2 | 2 | 4 | 1 | 2 | 10 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | 3 | 2 | — | 5 |
| Healthy volunteers/patients | — | — | — | — | 2 | — | 2 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | 1 | — | 2 |
| Drug interactions | D004347 | — | — | — | 1 | — | 1 | ||
| Glucosephosphate dehydrogenase deficiency | D005955 | EFO_0007287 | — | — | — | 1 | — | 1 | |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 2 | — | — | 2 |
| Pregnancy rate | D018873 | — | — | 2 | — | — | 2 | ||
| Fever | D005334 | HP_0001945 | R50.9 | — | — | 1 | — | — | 1 |
| Asymptomatic diseases | D058070 | — | — | 1 | — | — | 1 | ||
| Bacterial vaginosis | D016585 | EFO_0003932 | — | — | 1 | — | — | 1 | |
| Trichomonas vaginitis | D014247 | EFO_0007521 | — | — | 1 | — | — | 1 | |
| Hiv | D006678 | O98.7 | — | — | 1 | — | — | 1 | |
| Filarial elephantiasis | D004605 | EFO_0007272 | B74.0 | — | — | 1 | — | — | 1 |
| Scabies | D012532 | B86 | — | — | 1 | — | — | 1 | |
| Strongyloidiasis | D013322 | EFO_0007501 | B78 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiotoxicity | D066126 | EFO_1001482 | — | 1 | — | — | — | 1 | |
| Parasitemia | D018512 | — | 1 | — | — | — | 1 | ||
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ARTENIMOL |
| INN | artenimol |
| Description | Dihydroartemisinin is a sesquiterpenoid compound which is used as a drug for treatment of malaria. It has a role as an antimalarial. |
| Classification | Small molecule |
| Drug class | antimalarials (artemisin derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4 |
Identifiers
| PDB | — |
| CAS-ID | 71939-50-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL252518 |
| ChEBI ID | — |
| PubChem CID | 6918483 |
| DrugBank | DB11638 |
| UNII ID | 6A9O50735X (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 884 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
72,770 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more